PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
269.37%
Net income growth above 1.5x VET's 103.69%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
-0.25%
Both reduce yoy D&A, with VET at -3.72%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
-267.27%
Negative yoy deferred tax while VET stands at 136.72%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
-146.15%
Both cut yoy SBC, with VET at -33.54%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
62.33%
Slight usage while VET is negative at -75.93%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
62.33%
Some yoy usage while VET is negative at -75.93%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
-10.00%
Both negative yoy, with VET at -485.91%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
63.91%
Some CFO growth while VET is negative at -6.10%. John Neff would note a short-term liquidity lead over the competitor.
10.63%
Lower CapEx growth vs. VET's 58.69%, potentially boosting near-term free cash. David Dodd would confirm no missed expansions that competitor might exploit.
262.79%
Some acquisitions while VET is negative at -100.00%. John Neff sees competitor possibly pausing M&A or divesting while the firm invests in new deals.
-103.08%
Negative yoy purchasing while VET stands at 0.00%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
317.65%
Liquidation growth of 317.65% while VET is zero at 0.00%. Bruce Berkowitz sees a mild difference in monetizing portfolio items that must be justified by market valuations.
5.77%
We have some outflow growth while VET is negative at -297.89%. John Neff sees competitor possibly pulling back more aggressively from minor expansions or intangible invests.
20.04%
We have mild expansions while VET is negative at -8.06%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
50.00%
We repay more while VET is negative at -0.82%. John Neff notes advantage in lowering leverage if competitor is ramping up debt or repaying less.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.